At present, the treatment of AML mainly includes chemotherapy and molecular targeted therapy, such as FMS-like tyrosine kinase 3 (FLT3) inhibitors, IDH [isocitrate dehydrogenase (NADP+)] inhibitors, and monoclonal antibodies [23]. The gene discussed is FLT3; the disease is acute myeloid leukemia.